| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803160501039 | 316050103 | TEMOZOLOMIDE ACCORD CAPS 5MG/CAP Φακελίσκος x 5 καψάκια | 4.98 | 5.22 | 7.20 |
| 05/2018 | 2803160502036 | 316050203 | TEMOZOLOMIDE ACCORD CAPS 20MG/CAP Φακελίσκος x 5 καψάκια | 14.61 | 15.33 | 21.13 |
| 05/2018 | 2803160503033 | 316050303 | TEMOZOLOMIDE ACCORD CAPS 100MG/CAP Φακελίσκος x 5 καψάκια | 51.90 | 54.44 | 69.25 |
| 05/2018 | 2803160504030 | 316050403 | TEMOZOLOMIDE ACCORD CAPS 140MG/CAP Φακελίσκος x 5 καψάκια | 104.12 | 109.22 | 134.30 |
| 05/2018 | 2803160505037 | 316050503 | TEMOZOLOMIDE ACCORD CAPS 180MG/CAP Φακελίσκος x 5 καψάκια | 126.68 | 132.89 | 163.40 |
| 05/2018 | 2803160506034 | 316050603 | TEMOZOLOMIDE ACCORD CAPS 250MG/CAP Φακελίσκος x 5 καψάκια | 186.64 | 195.78 | 236.58 |
| 05/2018 | 2803134401013 | 313440101 | TEMOZOLOMIDE SANDOZ CAPS 5MG/CAP Φιάλη γυάλινη x 5 CAPS | 4.98 | 5.22 | 7.20 |
| 05/2018 | 2803134402010 | 313440201 | TEMOZOLOMIDE SANDOZ CAPS 20MG/CAP Φιάλη γυάλινη x 5 CAPS | 14.61 | 15.33 | 21.13 |
| 05/2018 | 2803134403017 | 313440301 | TEMOZOLOMIDE SANDOZ CAPS 100MG/CAP Φιάλη γυάλινη x 5 CAPS | 51.90 | 54.44 | 69.25 |
| 05/2018 | 2803134404014 | 313440401 | TEMOZOLOMIDE SANDOZ CAPS 140MG/CAP Φιάλη γυάλινη x 5 CAPS | 104.12 | 109.22 | 134.30 |
| 05/2018 | 2803134405011 | 313440501 | TEMOZOLOMIDE SANDOZ CAPS 180MG/CAP Φιάλη γυάλινη x5 CAPS | 126.68 | 132.89 | 163.40 |
| 05/2018 | 2803134406018 | 313440601 | TEMOZOLOMIDE SANDOZ CAPS 250MG/CAP Φιάλη γυάλινη x 5 CAPS | 186.64 | 195.78 | 236.58 |
For the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme. Also used as maintenance therapy for glioblastoma multiforme.
Temozolomide is not active until it is converted at physiologic pH to MTIC. It is suggested that MTIC then alkylates DNA at the N7 position of guanine, O3 position of adenosine, and O6 position of guanosine, with the most common site being the N7 position. This methylation of guanine residues lead to single and double-strand DNA breaks and subsequent apoptotic cell death. It is suggested that the N7-methylguanine plays a critical role in the antitumor activity of the drug, as there is a correlation between the sensitivity of tumor cell lines to temozolomide and the activity of O6-alkylguanine alkyltransferase, which is the DNA repair protein that specifically removes alkyl groups at the O6 position of guanine. Cells lines that have lower levels of AGT are more sensitive to the cytotoxicity of temozolomide. It is also suggested that cytotoxic mechanism of temozolomide is related to the failure of the DNA MMR system to find a complementary base for methylated guanine. The DNA MMR system is involved in the formation of a number of proteins that remove methylated guanine. Evidence shows that when this repair process is targeted to the DNA strand opposite the O6-methylguanine, its inability to find the correct target leads to long-lived nicks in the DNA. The accumulation of these nicks lead to the inhibition of replication in the daughter cells, thereby blocking the cell cycle at the G<sub>2</sub>-M boundary.
Rapid and complete absorption in the gastrointestinal tract
Approximately 1.8 hours.
About 38% of the administered temozolomide total radioactive dose is recovered over 7 days: 37.7% in urine and 0.8% in feces.
* 0.4 L/kg
* 5.5 L/hr/m2